Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No benefit with postoperative radiotherapy in stage IIIAN2 NSCLC

Key clinical point: In patients with completely resected non–small cell lung cancer and proven N2 disease, postoperative radiotherapy provided no significant improvement in disease-free survival.

Major finding: The 3-year disease-free survival rate was 43.8% without postoperative radiotherapy and 47.1% with PORT (hazard ratio, 0.85, P = .16).

Study details: The phase 3 Lung ART trial included 501 completely resected non–small cell lung cancer patients with mediastinal N2 nodal involvement randomized 1:1 to conformal PORT (54 Gy/5.5 weeks) or no PORT.

Disclosures: The study was sponsored by Gustave Roussy and supported by the French National Cancer Institute, French Health Ministry, and a Cancer Research UK grant. Dr. Le Péchoux reported no conflicts of interest related to the presentation.

Citation:

Le Péchoux C et al. ESMO 2020, Abstract LBA3_PR.